György M. Keserű obtained his Ph.D. at Budapest, Hungary. He worked for Sanofi and then moved to Gedeon Richter. In 2007 he was appointed as the Head of Discovery Chemistry. He contributed to the discovery of the antipsychotic Vraylar® (cariprazine) that has been approved and marketed from 2016 in US and EU. He served as a director general of the Research Centre for Natural Sciences (RCNS), Hungary. Since 2015 he is heading the Medicinal Chemistry Research Group at RCNS and is a full professor at the Budapest University of Technology and Economics. His research interests include medicinal chemistry and drug design. György was awarded with the prestigious Overton and Meyer Award of the European Federation of Medicinal Chemistry and recently he has been elected as a corresponding member of the Hungarian Academy of Sciences.